January 2019 in “프로그램북(구 초록집)” This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.
March 2026 in “Immunological Medicine” This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.
July 2026 in “American Journal of Clinical Dermatology” In this study, oral JAK inhibitors were found to be significantly more effective than placebo in promoting hair regrowth among adults and adolescents with moderate-to-severe alopecia areata, although they were associated with an increased risk of adverse events.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.
